Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852000 | 0.85 | ESR1 (0.58) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5852042 | 0.77 | ESR1 (0.60) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5851561 | 0.75 | ESR1 (0.65) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5852051 | 0.74 | ESR1 (0.56) | ESR1ESR2 | |
| SCHEMBL5852085 | 0.71 | ESR1 (0.61) | ESR1EBPSIGMAR1 | |
| SCHEMBL6295550 | 0.71 | ESR1 (0.61) | ESR1EBPSIGMAR1 | |
| SCHEMBL7554561 | 0.70 | ESR1 (0.43) | ESR1ESR2 | |
| SCHEMBL3922593 | 0.69 | ESR1 (0.59) | ESR1EBPSIGMAR1 | |
| SCHEMBL5851994 | 0.69 | ESR1 (0.59) | ESR1EBPSIGMAR1 | |
| SCHEMBL5852746 | 0.69 | ESR1 (0.60) | ESR1ESR2EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878750-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2005-04-12 | — | — | US | claimed |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-03-13 | — | — | US | claimed |
| US-6495607-B2 | 8,9-DIHYDRO-7H-BENZOCYCLOHEPTENE DERIVATIVES ARE USEFUL FOR PHOPHYLAXIS AND THERAPY OF OSTEOPOROSIS(HAVE SELECTIVE ESTROGENIC ACTIVITY ON BONES) | SCHERING AG (DE) | 2002-12-17 | — | — | US | claimed |
| US-20020068765-A1 | BENZOCYCLOHEPTENES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-06 | — | — | US | claimed |
| US-7145015-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain that latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2006-12-05 | — | — | US | disclosed |
| US-20050182081-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | US | disclosed |
| US-6878750-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2005-04-12 | — | — | US | disclosed |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-03-13 | — | — | US | disclosed |
| US-6495607-B2 | 8,9-DIHYDRO-7H-BENZOCYCLOHEPTENE DERIVATIVES ARE USEFUL FOR PHOPHYLAXIS AND THERAPY OF OSTEOPOROSIS(HAVE SELECTIVE ESTROGENIC ACTIVITY ON BONES) | SCHERING AG (DE) | 2002-12-17 | — | — | US | disclosed |
| US-20020068765-A1 | BENZOCYCLOHEPTENES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068765-A1 | BENZOCYCLOHEPTENES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | CYP19A1, ESRRA, SULT2A1 | ESR1 36/4885ESR2 5/4885HDAC3 1768/4885 |
| US-20050182081-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | CYP19A1, ESR2, ESRRA | ESR1 8/4885ESR2 2/4885HDAC3 1656/4885 |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | CYP19A1, ESRRA, SULT2A1 | ESR1 36/4885ESR2 5/4885HDAC3 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.